Therapeutic inhibitor of vascular smooth muscle cells
CA 2455985 A1 · Owner: Klein, Richard A. · Inventors: Metcalfe, James C.; Grainger, David J.; Weissberg, Peter L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Sustained release dosage forms of TGF-beta activators and TGFbeta production stimulators are employed to maintain or increase vessel lumen diameter in a diseased or injured vessel of a mammal. Conditions such as restenosis following angioplasty, vascular bypass grafts, transplanted organs atherosclerosis or hypertension are characterized by a reduced vessel lumen diameter. In a preferred embodiment of the invention, TGF-beta activators and production stimulators inhibit abnormal proliferation of smooth muscle cells. Free TGF-beta activators or production stimulators that are not characterized by an undesirable systemic toxicity profile at a prophylactic dose may be used in conjunction with …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 12, 1994. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 12, 2014.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 12, 2016.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.